Cinthya A Pena Orbea1, Robin M Lloyd2, Stephanie S Faubion3, Virginia M Miller4, Kristin C Mara5, Ekta Kapoor6. 1. Center for Sleep Medicine, Mayo Clinic, Rochester, MN, United States. 2. Center for Sleep Medicine, Mayo Clinic, Rochester, MN, United States; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, United States. 3. Division of General Internal Medicine, Mayo Clinic, Rochester, MN, United States. 4. Division of Surgery Research, Mayo Clinic, Rochester, MN, United States; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States. 5. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States. 6. Division of General Internal Medicine, Mayo Clinic, Rochester, MN, United States; Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, United States. Electronic address: kapoor.ekta@mayo.edu.
Abstract
OBJECTIVES: The STOP-BANG questionnaire (snoring, tiredness, observed apneas, high blood pressure, body mass index, age, neck size, gender) was originally validated to screen for obstructive sleep apnea (OSA) in the surgical population. It has been validated in mixed populations of men and women. We aimed to evaluate its reliability for OSA screening of midlife women. STUDY DESIGN: We retrospectively evaluated midlife women seen at the Women's Health Clinic at Mayo Clinic in Rochester, Minnesota, who completed the STOP-BANG questionnaire and subsequently underwent diagnostic polysomnography (PSG) or home sleep apnea testing (HSAT). MAIN OUTCOME MEASURES: The questionnaire's predictive ability was assessed with the apnea hypopnea index (AHI) measured at PSG and HSAT. RESULTS: Because participants were female, the gender question response was consistently 0, making the mean (SD) STOP-BANG score low at 3 (1.2). The most sensitive item to detect any OSA and moderate to severe OSA through STOP-BANG was observed apneas; the most specific item to detect OSA and moderate to severe OSA was neck circumference exceeding 40 cm. A score of 3 or more had a sensitivity of 77 % and a specificity of 45 % to detect moderate to severe OSA. The area under the curve with the STOP-BANG score to predict moderate to severe OSA was 0.67 (95 % CI, 0.51-0.84). CONCLUSIONS: Interpretation of the STOP-BANG questionnaire is nuanced for midlife women. Given the nature of its questions, a lower score may be predictive of more severe OSA in women, necessitating use of a lower threshold to trigger further testing.
OBJECTIVES: The STOP-BANG questionnaire (snoring, tiredness, observed apneas, high blood pressure, body mass index, age, neck size, gender) was originally validated to screen for obstructive sleep apnea (OSA) in the surgical population. It has been validated in mixed populations of men and women. We aimed to evaluate its reliability for OSA screening of midlife women. STUDY DESIGN: We retrospectively evaluated midlife women seen at the Women's Health Clinic at Mayo Clinic in Rochester, Minnesota, who completed the STOP-BANG questionnaire and subsequently underwent diagnostic polysomnography (PSG) or home sleep apnea testing (HSAT). MAIN OUTCOME MEASURES: The questionnaire's predictive ability was assessed with the apnea hypopnea index (AHI) measured at PSG and HSAT. RESULTS: Because participants were female, the gender question response was consistently 0, making the mean (SD) STOP-BANG score low at 3 (1.2). The most sensitive item to detect any OSA and moderate to severe OSA through STOP-BANG was observed apneas; the most specific item to detect OSA and moderate to severe OSA was neck circumference exceeding 40 cm. A score of 3 or more had a sensitivity of 77 % and a specificity of 45 % to detect moderate to severe OSA. The area under the curve with the STOP-BANG score to predict moderate to severe OSA was 0.67 (95 % CI, 0.51-0.84). CONCLUSIONS: Interpretation of the STOP-BANG questionnaire is nuanced for midlife women. Given the nature of its questions, a lower score may be predictive of more severe OSA in women, necessitating use of a lower threshold to trigger further testing.
Authors: Mako Nagayoshi; Naresh M Punjabi; Elizabeth Selvin; James S Pankow; Eyal Shahar; Hiroyasu Iso; Aaron R Folsom; Pamela L Lutsey Journal: Sleep Med Date: 2016-09-29 Impact factor: 3.492
Authors: Tianyi Huang; Brian M Lin; Sarah C Markt; Meir J Stampfer; Francine Laden; Frank B Hu; Shelley S Tworoger; Susan Redline Journal: Eur Respir J Date: 2018-03-15 Impact factor: 16.671
Authors: Esther Quintana-Gallego; Carmen Carmona-Bernal; Francisco Capote; Angeles Sánchez-Armengol; Georgina Botebol-Benhamou; Juan Polo-Padillo; Jóse Castillo-Gómez Journal: Respir Med Date: 2004-10 Impact factor: 3.415
Authors: Mini Singh; Ronald Gavidia; Galit Levi Dunietz; Elizabeth Washnock-Schmid; Andrew R Romeo; Shelley Hershner; Ronald D Chervin; Tiffany J Braley Journal: Mult Scler Date: 2021-05-28 Impact factor: 6.312
Authors: Naima Laharnar; Sebastian Herberger; Lisa-Kristin Prochnow; Ning-Hung Chen; Peter A Cistulli; Allan I Pack; Richard Schwab; Brendan T Keenan; Diego R Mazzotti; Ingo Fietze; Thomas Penzel Journal: Nat Sci Sleep Date: 2021-11-09